The Drug Controller General of India (DCGI) has banned use of popular anti-cold cocktail medicine combination for children ...

GSK GSK-0.10 ... Thursday after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands of U.S. lawsuits over claims its discontinued heartburn medicine Zantac caused ...

GSK Pharma board approves sale of Vemgal plant to Hetero Labs The board of directors at its meeting held on Tuesday, approved the sale of the company's business undertaking i.e., manufacturing ...

New Delhi: At least 6% cough syrup samples belonging to 54 Indian pharmaceutical manufacturers failed the mandatory quality test for export till October this year, according to government data.

GSK GSK0.13%increase ... in the U.S. over allegations its discontinued heartburn medicine Zantac causes cancer. The British pharmaceutical giant said Wednesday that it had struck agreements ...

GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals. The company's product portfolio includes prescription medicines and ...

GlaxoSmithKline Pharma, celebrating 100 years in India, is shifting to a specialty-focused model by entering the oncology market and expanding its preventive healthcare through adult vaccines.

Research firm PharmaTrac data shows Augmentin sales at Rs 801 crore from November 2022-23. For the month of November, Augmentin sales stood at Rs 75 crore. It has shown a moving annual total (MAT ...

GlaxoSmithKline’s new head of pharmaceuticals, Luke Miels, will start work in September, after the company settled a contract dispute with UK rivals AstraZeneca. GSK poached Miels from ...

GlaxoSmithKline Pharmaceuticals ... distributing and trading in pharmaceuticals. The Company has three product areas: vaccines, specialty and general medicine. Its general medicines business ...

Antibodies from the Abrysvo vaccine will be passed from the mothers to the babies. Read more at straitstimes.com.

View upcoming earnings forecasts and in-depth analysis of company forecasts.